when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Merck KGaA · news · pharmadog

← back to Merck KGaA

News mentioning Merck KGaA

26 stories

3dFoghorn cuts 40% of workforcebiospace

4dSTAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the worldstat

4dFDA starts review of Roche’s multiple sclerosis pillbiopharma dive

13dBoehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenicsbiospace

17dBMS scraps Orum’s targeted degrader after reviewing Phase 1 databiospace

26dCancer biotech TwoStep gets $62.5M to take twist on ADCs into clinicendpoints

26dBeeline flies into phase 3 as oral lupus drug soars past placebofiercebiotech

27dInhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityfiercebiotech

Aug 27, 26A year on from Big Pharma’s pull-back from the UK, has anything changed?fiercebiotech

Aug 21, 26Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drugfiercebiotech

Aug 20, 26Out of sight, out of work? What’s driving remote job cutsbiospace

Aug 17, 26Merck KGaA lays off 20 staffers in latest blow to US research teamfiercebiotech

Aug 17, 26Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vaguefiercebiotech

Aug 13, 26July's biopharma layoffs affect 466 employees, a 94% year-over-year dropbiospace

Aug 11, 26Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsfiercebiotech

Aug 10, 26MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialfiercebiotech

Aug 6, 26Merck KGaA readies tariff refunds worth €40M for life science customersendpoints

Aug 5, 26Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’fiercebiotech

Jul 30, 26Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continuesfiercebiotech

Jun 26, 26FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesbiopharma dive

May 13, 26Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boostendpoints

May 12, 26Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionbiopharma dive

Apr 24, 26Sanofi MS drug rejected in US gets an endorsement in Europebiopharma dive

Apr 23, 26Sanofi posts upbeat sales as R&D pressure buildsbiopharma dive

Apr 23, 26Sanofi defends Garijo appointment, says it is 'fully committed' to immunologyendpoints

Dec 23, 25Fierce Biotech Layoff Tracker 2026: Foghorn cuts workforce by 40%; BioMarin drops 117 rolesfiercebiotech